The DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Published version of a preprint
Abstract
MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. RG7112 is a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies. RG7112 binds MDM2 with high affinity (KD ∼ 11 nmol/L), blocking its interactions with p53 in vitro. A crystal structure of the RG7112–MDM2 complex revealed that the small molecule binds in the p53 pocket of MDM2, mimicking the interactions of critical p53 amino acid residues. Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis. RG7112 showed potent antitumor activity against a panel of solid tumor cell lines. However, its apoptotic activity varied widely with the best response observed in osteosarcoma cells with MDM2 gene amplification. Interestingly, inhibition of caspase activity did not change the kinetics of p53-induced cell death. Oral administration of RG7112 to human xenograft-bearing mice at nontoxic concentrations caused dose-dependent changes in proliferation/apoptosis biomarkers as well as tumor inhibition and regression. Notably, RG7112 was highly synergistic with androgen deprivation in LNCaP xenograft tumors. Our findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53. Cancer Res; 73(8); 2587–97. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This time point was selected because signs of cell death started to occur only 20–25 h after addition of RG7112, an observation that is consistent with a previously published report [20].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [20]
In the citing paper
“In vivo studies show that a single oral administration of RG-7112 can activate p53 pathway, induce tumor cell apoptosis, reduce tumor growth and improve survival in GBM models.370,371”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [370]
In the citing paper
“Presumably, p53 induces cell cycle arrest to protect cells from propagation of damaged DNA before it is repaired, whereas apoptosis eliminates cells with unrepairable damage [44].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [44]
In the citing paper
“Restoration of p53 is known to block cell-cycle progression and induces apoptosis in the presence of MDM2-p53 interaction antagonists [43–45].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [44]
In the citing paper
“RG7112 has been demonstrated to have growth inhibition and killing effects on SJSA-1 osteosarcoma cells with a high expression of MDM2 protein in vitro. Dose-dependent cell cycle arrest was induced in HCT116 and SJSA1 cells at the G1 and G2/M phases [23].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [23]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 1×
“The tumor suppressor effectively arrests cellcycle progression in G1 and G2 phases primarily attributed to induction of the p53 transcriptional target and pan-cyclin– dependent kinase inhibitor, p21 (19, 20).”
BackgroundVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651 · cited 1×
“The tumor suppressor effectively arrests cell cycle progression in G1 and G2 phases primarily attributed to induction of the p53 transcriptional target and pan-CDK inhibitor, p21 (19, 20).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 9×
“1C) revealed that the small molecule binds in the same fashion to the p53 pocket as was first described for nutlin-2 (15).”
BackgroundMethodResultInfluentialSelf-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“MDM2 is also a p53specific E3 ubiquitin ligase that targets p53 for ubiquitindependent degradation in the proteasome (6, 7).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“Stress-induced p53 activation mechanisms in these tumors are believed to be inadequate, leading to inefficient growth arrest and/or apoptosis (11).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“Genetic and biochemical studies mapped p53-MDM2 binding sites to the N-terminal domain of MDM2 and the Nterminal part of the transactivation domain of p53 (5).”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 2×
“The crystal structure of a p53-derived peptide bound to the p53binding domain of MDM2 revealed the existence of a relatively deep cavity on the surface of the MDM2 molecule (14).”
BackgroundThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · cited 1×
“It is a transcription factor which is activated following stress and regulates multiple downstream genes implicated in cell cycle control, apoptosis, DNA repair, and senescence (1, 2).”
BackgroundInfluentialAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“Therefore, blocking the p53-MDM2 interaction is expected to overcome the oncogenic consequences of MDM2 overproduction and to restore p53 function (12, 13).”
Background
Cited by
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
“Nutlins, a group of cis-imidazoline small-molecule compounds, have shown selective inhibition of the MDM2:p53 interaction in preclinical studies.(103,104) Nutlins have also been shown in human xenograft models to inhibit wild-type p53 tumor growth in a dose-dependent manner and even exhibited regression in some instan…”
BackgroundSmall-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
“These clinical-stage inhibitors show impressive tumor regressions in xenograft models and selective killing of cells containing wild-type p53 versus those with mutant p53 (Tovar et al., 2013).”
BackgroundMethodTargeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“The best responses were observed in MDM2 gene-amplified osteosarcoma cell lines and xenografts.(341,343)”
BackgroundTargeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Metadata
- Authors
- Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., Linn, M., Podlaski, F., Wovkulich, P., Vu, B., & Vassilev, L. T.
- Affiliations
- Authors' Affiliation: Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey
- Venue
- Cancer Research
- Published
- 2013-04-15
- Volume
- 73
- Issue
- 8
- Pages
- 2587-2597
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2098748257
- Cited by
- 283
- References
- 26
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 30 · 2022: 24 · 2021: 19 · 2020: 19 · 2019: 19 · 2018: 16 · 2017: 19 · 2016: 30 · 2015: 37 · 2014: 29 · 2013: 12
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- RG7112, nutlin, MDM2 inhibitors, p53 activation, p53 stabilization, cell cycle arrest, apoptosis, solid tumors, osteosarcoma, MDM2 amplification, LNCaP xenografts, androgen deprivation therapy, caspase inhibition, oral antitumor activity
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Female, Humans, Neoplasms, Protein Binding, Signal Transduction, Tumor Suppressor Protein p53, Apoptosis, Caspases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Imidazolines, Mice, Proto-Oncogene Proteins c-mdm2, Protein Stability, Cell Cycle Checkpoints, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2807
- The paper
- Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., Linn, M., Podlaski, F., Wovkulich, P., Vu, B., & Vassilev, L. T. (2013). MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.